{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:12:04Z","timestamp":1757700724201,"version":"3.40.5"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The use of broad-spectrum antibiotics is widespread in patients with COVID-19 despite a low prevalence of bacterial co-infection, raising concerns for the accelerated development of antimicrobial resistance. Antimicrobial stewardship (AMS) is vital but there are limited randomized clinical trial data supporting AMS interventions such as prospective audit and feedback (PAF). High quality data to demonstrate safety and efficacy of AMS PAF in hospitalized COVID-19 patients are needed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and design<\/jats:title>\n<jats:p>This is a prospective, multi-center, non-inferiority, pragmatic randomized clinical trial evaluating AMS PAF intervention plus standard of care (SOC) versus SOC alone. We include patients with microbiologically confirmed SARS-CoV-2 infection requiring hospital admission for severe COVID-19 pneumonia. Eligible ward beds and critical care unit beds will be randomized prior to study commencement at each participating site by computer-generated allocation sequence stratified by intensive care unit versus conventional ward in a 1:1 fashion. PAF intervention consists of real time review of antibacterial prescriptions and immediate written and verbal feedback to attending teams, performed by site-based AMS teams comprised of an AMS pharmacist and physician. The primary outcome is clinical status at post-admission day 15 measured using a 7-point ordinal scale. Patients will be followed for secondary outcomes out to 30 days. A total of 530 patients are needed to show a statistically significant non-inferiority, with 80% power and 2.5% one-sided alpha assuming standard deviation of 2 and the non-inferiority margin of 0.5.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>This study protocol presents a pragmatic clinical trial design with small unit cluster randomization for AMS intervention in hospitalized COVID-19 that will provide high-level evidence and may be adopted in other clinical situations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>This study is being performed at the University of Alberta and is registered at ClinicalTrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04896866\" xlink:type=\"simple\">NCT04896866<\/jats:ext-link>) on May 17, 2021.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0265493","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:34:01Z","timestamp":1648056841000},"page":"e0265493","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19: A protocol for a pragmatic clinical trial"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-5857","authenticated-orcid":true,"given":"Justin Z.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly L.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryna","family":"Yaskina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Kabbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E.","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-0083","authenticated-orcid":true,"given":"Stephanie W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackson","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Zurek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0161-1749","authenticated-orcid":true,"given":"Carlos","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"issue":"5","key":"pone.0265493.ref001","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"E Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0265493.ref002","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s12879-018-3548-0","article-title":"The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09.","volume":"18","author":"CR MacIntyre","year":"2018","journal-title":"BMC Infect Dis."},{"key":"pone.0265493.ref003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2016.04.008","article-title":"Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013\u201314.","volume":"80","author":"NS Shah","year":"2016","journal-title":"J Clin Virol"},{"issue":"12","key":"pone.0265493.ref004","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis","volume":"26","author":"BJ Langford","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"pone.0265493.ref005","article-title":"Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing","author":"TM Rawson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0265493.ref006","first-page":"CD015025","article-title":"Antibiotics for the treatment of COVID-19.","volume":"10","author":"M Popp","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"pone.0265493.ref007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1086\/512174","article-title":"An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia.","volume":"28","author":"PM Polgreen","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"pone.0265493.ref008","article-title":"Guidance On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society","author":"JL Sapp","year":"2020","journal-title":"The Canadian journal of cardiology"},{"issue":"4","key":"pone.0265493.ref009","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cmi.2020.12.018","article-title":"Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis","volume":"27","author":"BJ Langford","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"pone.0265493.ref010","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2666-5247(21)00173-7","article-title":"Collaborators. Rising antimicrobial resistance: an evolving epidemic in a pandemic","volume":"2","author":"A Manesh","year":"2021","journal-title":"Lancet Microbe"},{"issue":"9","key":"pone.0265493.ref011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11908-020-00734-x","article-title":"Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs.","volume":"22","author":"H Mazdeyasna","year":"2020","journal-title":"Curr Infect Dis Rep."},{"key":"pone.0265493.ref012","article-title":"COVID-19, superinfections and antimicrobial development: What can we expect?","author":"CJ Clancy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0265493.ref013","first-page":"1","article-title":"Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck.","author":"MP Stevens","year":"2020","journal-title":"Infection Control & Hospital Epidemiology."},{"issue":"4","key":"pone.0265493.ref014","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/pch\/pxaa066","article-title":"Combined influence of practice guidelines and prospective audit and feedback stewardship on antimicrobial treatment of community-acquired pneumonia and empyema in children: 2012 to 2016.","volume":"26","author":"NMA Le Saux","year":"2021","journal-title":"Paediatr Child Health"},{"issue":"6","key":"pone.0265493.ref015","doi-asserted-by":"crossref","first-page":"ofab186","DOI":"10.1093\/ofid\/ofab186","article-title":"Using Audit and Feedback to Improve Antimicrobial Prescribing in Emergency Departments: A Multicenter Quasi-Experimental Study in the Veterans Health Administration.","volume":"8","author":"DJ Livorsi","year":"2021","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"pone.0265493.ref016","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/ice.2017.296","article-title":"Quasi-experimental Studies in the Fields of Infection Control and Antibiotic Resistance, Ten Years Later: A Systematic Review.","volume":"39","author":"R Alsaggaf","year":"2018","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"11","key":"pone.0265493.ref017","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/420936","article-title":"The use and interpretation of quasi-experimental studies in infectious diseases","volume":"38","author":"AD Harris","year":"2004","journal-title":"Clin Infect Dis"},{"key":"pone.0265493.ref018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13756-019-0471-0","article-title":"Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review.","volume":"8","author":"D Nathwani","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"pone.0265493.ref019","unstructured":"The COVID-19 Antimicrobial Management Working Group AHS. Current Guidance for the Management of Adult Hospitalized Patients with COVID-19: Alberta Health Services; 2020 [Available from: https:\/\/www.albertahealthservices.ca\/assets\/info\/ppih\/if-ppih-covid-19-recommendations.pdf]."},{"issue":"3","key":"pone.0265493.ref020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"AP Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"pone.0265493.ref021","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"VC Veiga","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"pone.0265493.ref022","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"TF Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pone.0265493.ref023","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1017\/ice.2016.117","article-title":"Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship-Quasi-Experimental Designs.","volume":"37","author":"ML Schweizer","year":"2016","journal-title":"Infect Control Hosp Epidemiol."},{"key":"pone.0265493.ref024","first-page":"CD003543","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients.","volume":"2","author":"P Davey","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"7","key":"pone.0265493.ref025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1473-3099(16)00065-7","article-title":"Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis","volume":"16","author":"EC Schuts","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0265493.ref026","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cmi.2018.11.002","article-title":"The quality of studies evaluating antimicrobial stewardship interventions: a systematic review","volume":"25","author":"VA Schweitzer","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"pone.0265493.ref027","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/664755","article-title":"Antimicrobial stewardship\u2014the state of the art in 2011: focus on outcome and methods.","volume":"33","author":"JE McGowan","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"pone.0265493.ref028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40506-014-0015-3","article-title":"Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact.","volume":"6","author":"AM Morris","year":"2014","journal-title":"Curr Treat Options Infect Dis."},{"issue":"19","key":"pone.0265493.ref029","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0265493.ref030","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/599172","article-title":"Antimicrobial stewardship programs in inpatient hospital settings: a systematic review.","volume":"35","author":"B Wagner","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"pone.0265493.ref031","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/jim-2020-001481","article-title":"High-impact RCTs without prospective informed consent: a systematic review.","volume":"68","author":"R Dhamanaskar","year":"2020","journal-title":"J Investig Med"},{"issue":"12","key":"pone.0265493.ref032","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11606-016-3780-5","article-title":"Proposals to Conduct Randomized Controlled Trials Without Informed Consent: a Narrative Review","volume":"31","author":"JH Flory","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"7","key":"pone.0265493.ref033","doi-asserted-by":"crossref","first-page":"e40436","DOI":"10.1371\/journal.pone.0040436","article-title":"Participant informed consent in cluster randomized trials: review.","volume":"7","author":"B Giraudeau","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"pone.0265493.ref034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/eahr.500071","article-title":"Loopholes in the Research Ethics System? Informed Consent Waivers in Cluster Randomized Trials with Individual-Level Intervention.","volume":"42","author":"AJ London","year":"2020","journal-title":"Ethics Hum Res."},{"key":"pone.0265493.ref035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1745-6215-12-202","article-title":"When is informed consent required in cluster randomized trials in health research?","volume":"12","author":"AD McRae","year":"2011","journal-title":"Trials"},{"issue":"3","key":"pone.0265493.ref036","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2105\/AJPH.2011.300389","article-title":"Informed consent and cluster-randomized trials.","volume":"102","author":"J Sim","year":"2012","journal-title":"Am J Public Health"},{"issue":"7","key":"pone.0265493.ref037","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2471\/BLT.20.268573","article-title":"Tackling antimicrobial resistance in the COVID-19 pandemic","volume":"98","author":"H Getahun","year":"2020","journal-title":"Bull World Health Organ"},{"issue":"2","key":"pone.0265493.ref038","article-title":"Assessing the Impact of COVID-19 on Antimicrobial Stewardship Activities\/Programs in the United Kingdom.","volume":"10","author":"D Ashiru-Oredope","year":"2021","journal-title":"Antibiotics (Basel)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:34:40Z","timestamp":1648056880000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265493"}},"subtitle":[],"editor":[{"given":"Dafna","family":"Yahav","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0265493","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}